A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]

Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) regulates LDL cholesterol levels by inhibiting LDL receptor (LDLr)-mediated cellular LDL uptake. We have identified a fragment antigen-binding (Fab) 1D05 which binds PCSK9 with nanomolar affinity. The fully human antibody 1D05-IgG2 completel...

Full description

Bibliographic Details
Main Authors: Yan G. Ni, Stefania Di Marco, Jon H. Condra, Laurence B. Peterson, Weirong Wang, Fubao Wang, Shilpa Pandit, Holly A. Hammond, Ray Rosa, Richard T. Cummings, Dana D. Wood, Xiaomei Liu, Matthew J. Bottomley, Xun Shen, Rose M. Cubbon, Sheng-ping Wang, Douglas G. Johns, Cinzia Volpari, Lora Hamuro, Jayne Chin, Lingyi Huang, Jing Zhang Zhao, Salvatore Vitelli, Peter Haytko, Douglas Wisniewski, Lyndon J. Mitnaul, Carl P. Sparrow, Brian Hubbard, Andrea Carfí, Ayesha Sitlani
Format: Article
Language:English
Published: Elsevier 2011-01-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520404985